Trial Overview

This Phase 3 trial evaluates tumor reduction by adding trastuzumab‑hyaluronidase (Herceptin Hylecta) or pertuzumab‑trastuzumab‑hyaluronidase (Phesgo) to standard chemotherapy (paclitaxel + carboplatin) in patients with HER2‑positive endometrial cancer. The study is sponsored by the NCI, initiated in November 2022, and is currently enrolling. By combining an antibody‑based therapy that binds the HER2 receptor to block proliferative signaling and promote immune‑mediated cytotoxicity with standard chemotherapy, a synergistic effect is anticipated.

Current Treatment Landscape

HER2‑positive endometrial cancer accounts for roughly 10 % of all endometrial cancers. Standard care typically consists of surgery followed by chemotherapy or radiotherapy, and HER2‑targeted therapies remain limited. FDA‑approved HER2 agents are largely confined to breast cancer, leaving a paucity of data in this indication. Consequently, it is necessary to validate whether a novel HER2‑targeted combination strategy can provide tangible benefit to patients.

Mechanism of Action and Differentiation

Herceptin Hylecta comprises trastuzumab‑hyaluronidase, while Phesgo combines pertuzumab, trastuzumab, and hyaluronidase. Hyaluronidase enhances tissue diffusion of the drug and markedly shortens subcutaneous injection time, improving patient convenience. Moreover, the antibodies bind the HER2 receptor to block downstream signaling, thereby inhibiting tumor proliferation and simultaneously inducing immune‑mediated cell death.

Potential Impact if Successful

If successful, the trial could lead to the first approved HER2‑targeted plus chemotherapy regimen for HER2‑positive endometrial cancer. This would be expected to improve progression‑free survival (PFS) and overall survival (OS) relative to chemotherapy alone, and the market for this indication is estimated at several hundred million dollars annually. Companies such as Roche could expand their HER2 portfolio and secure a new revenue growth driver.

Risks and Timeline

Because the study is still in the enrollment phase, patient accrual speed and data quality are critical variables, and an anticipated completion date has not been disclosed. The low prevalence of HER2 positivity may also limit statistical power. Ongoing monitoring of interim analyses and the safety profile will be essential.